High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable ...
CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application ...
Protara Therapeutics Inc. TARA reported updated 12-month Phase 2 data for TARA-002 in patients with Bacillus Calmette-Guérin ...
Also previously reported, there was no benefit for extended pelvic lymphadenectomy in the overall cohort for metastasis free ...
Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...
Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results